XTalks

MARCH 7, 2024

Industry professionals will explore the market, innovative formulations and nutritional solutions tailored to empower women toward optimal health and well-being. The test accurately identified a range of genetic abnormalities, including trisomies and microdeletions.

Genetics 115

Genetics Hormones Genome Genomics 115

The Pharma Data

OCTOBER 27, 2020

“The MassARRAY SARS-CoV-2 Panel is the only assay on the market with 5 viral genome targets multiplexed into a single reaction, making it robust against potential mutations arising in the viral genome,” said Dr. Darryl Irwin , Vice President of Scientific Affairs.

Genetic Analysis 52

Genetic Analysis Genome Genomics Reagent 52

XTalks

DECEMBER 1, 2020

As the research and medical community learns more about population variances in disease outcomes, whether as a result of regional genetic profiles, socioeconomic factors, or environmental inputs, it’s become necessary to ensure that clinical research trials include broad swaths of global participants. billion in 2019.

Clinical Trials 96

Clinical Trials Clinical Trials Trials Clinical Research 96

XTalks

DECEMBER 15, 2020

The plant-based market is growing in the mainstream food market and will expand into various categories in 2021. Technology breakthroughs have provided consumers with a variety of personalized nutrition options,” says Chang Liu, market analyst at Innova Market Insights.

Production 98

Production Manufacturing Marketing Sales 98

XTalks

DECEMBER 15, 2020

The plant-based market is growing in the mainstream food market and will expand into various categories in 2021. Technology breakthroughs have provided consumers with a variety of personalized nutrition options,” says Chang Liu, market analyst at Innova Market Insights.

Production 52

Production Manufacturing Marketing Sales 52

XTalks

JULY 29, 2024

Understanding Late-Onset Pompe Disease Pompe disease, also known as glycogen storage disease type II (GSD2) or acid maltase deficiency, is a rare genetic disorder with an approximate incidence of one in 40,000 births characterized by the deficiency of the enzyme acid alpha-glucosidase (GAA).

Clinical Trials 105

Clinical Trials Clinical Trials Trials Research 105

XTalks

JANUARY 6, 2025

Furthermore, CRISPR/Cas9 presents a promising avenue for overcoming genetic diseases in the near future. CAR-T cell therapies continue to dominate the pipeline for genetically modified cell therapies, with 97 percent of them targeting cancer. The global market for cell and gene therapies , valued at $5.9 billion in 2024 to $56.15

Gene Therapy 111

Gene Therapy RNA Gene Editing Gene 111